TerminatedNot applicableNCT05335278

Tolerability and Safety of Nintedanib in Myositis Associated Interstitial Lung Disease

Studying Interstitial lung disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Principal Investigator
Deborah Assayag, MD
Research Institute - McGill University Health Center
Intervention
Nintedanib 150 milligrams [Ofev](drug)
Enrollment
11 enrolled
Eligibility
18 years · All sexes
Timeline
20212025

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05335278 on ClinicalTrials.gov

Other trials for Interstitial lung disease

Additional recruiting or active studies for the same condition.

See all trials for Interstitial lung disease

← Back to all trials